Andrew Griffin

发表

Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.

A. Griffin, William Brown, Richard L Leff, 2017, The journal of pain : official journal of the American Pain Society.